Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06635850 · ClinicalTrials.gov registry record · Phase 2
A Study of Mosliciguat in PH-ILD
A Phase 2 study of Cardiovascular Diseases and Pulmonary Hypertension, sponsored by Pulmovant.
- Active
- Registry status
- Phase 2
- Development phase
- 135
- Enrollment target
- 18
- Study locations
NCT06635850: Active Phase 2 study of Cardiovascular Diseases and Pulmonary Hypertension, sponsored by Pulmovant.
NCT06635850 is a Phase 2 study of Cardiovascular Diseases and Pulmonary Hypertension that is active but no longer recruiting, run by Pulmovant. The registered enrollment target is 135 participants, below the 26,974-participant average among 300 other Cardiovascular Diseases trials with a reported enrollment target (99% lower). The trial reports 18 study locations across 15 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06635850, a Phase 2 study of Cardiovascular Diseases and Pulmonary Hypertension, is active but no longer recruiting, sponsored by Pulmovant.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 135 participants
- Enrollment target
- 18
- Study locations
Study Summary
This is a Phase 2, randomized, double-blind, placebo-controlled, multi-center clinical study to evaluate the safety and efficacy of inhaled mosliciguat in participants with pulmonary hypertension associated with interstitial lung disease (PH-ILD).
Primary Outcome
PVR evaluated using right heart catheterization (RHC).
Conditions Studied
Interventions
- DRUG Placebo
- DEVICE Dry Powder Inhaler
- DRUG Mosliciguat
Study Locations (18)
California
- Ronald Reagan UCLA Medical Center - Los Angeles
- University of California Davis School of Medicine - Sacramento
- Harbor-UCLA Medical Center - Torrance - Torrance
North Carolina
- Duke University Health System - Duke Clinic - Durham
- PulmonIx - Greensboro
Arizona
- Arizona Pulmonary Specialists - Phoenix
Florida
- Florida Lung, Asthma & Sleep Specialists/Clinical Research Specialists, LLC - Celebration
Illinois
- Northwestern University - Chicago
Iowa
- University of Iowa Hospitals and Clinics - Iowa City
Kansas
- University of Kansas Medical Center - Kansas City
Kentucky
- Norton Pulmonary Specialists - Louisville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 135 participants |
| Start Date | 2024-10-29 |
| Est. Completion | 2028-01 |
| Phase | Phase 2 |
What the registry record for NCT06635850 still lists
NCT06635850 is an interventional study that assigns participants to a tested intervention. The registered 135 participants enrollment target is mid-sized for trials with a published cap, below the 26,974-participant average among 300 other Cardiovascular Diseases trials with a reported enrollment target (99% lower).
The record links to 6 conditions, with Cardiovascular Diseases appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT06635850 lists 18 locations in 15 states (California, North Carolina, Arizona).
Frequently Asked Questions
What is clinical trial NCT06635850 about?
NCT06635850 is a clinical study titled "A Study of Mosliciguat in PH-ILD". This is a Phase 2, randomized, double-blind, placebo-controlled, multi-center clinical study to evaluate the safety and efficacy of inhaled mosliciguat in participants with pulmonary hypertension associated with interstitial lung disease (PH-ILD).
What is the current status of trial NCT06635850?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 135 participants. The study started on 2024-10-29. Estimated completion is 2028-01.
What conditions does trial NCT06635850 study?
This clinical trial studies the following conditions: Cardiovascular Diseases, Pulmonary Hypertension, Vascular Diseases, Interstitial Lung Disease, Lung Diseases.
What interventions are being tested in trial NCT06635850?
The interventions under investigation include: Placebo (DRUG), Dry Powder Inhaler (DEVICE), Mosliciguat (DRUG).
Who is sponsoring clinical trial NCT06635850?
This trial is sponsored by Pulmovant, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06635850 being conducted?
This trial has 18 study locations across Arizona, California, Florida, Illinois, Iowa. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cardiovascular Diseases
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06635850's enrollment target sits among peer trials
135 173rd of 300 higher than 128 of 300 other Cardiovascular Diseases trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cardiovascular Diseases trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
NAUTICAL: Effect of Natriuretic Peptide Augmentation on Cardiometabolic Health in Black Individuals
RECRUITING · Phase 2
-
Emergency Medicine Cardiovascular Risk Assessment for Lipid Disorders Trial
RECRUITING · Phase 2
-
A Study of Mosliciguat in Combination With Inhaled Treprostinil in PH-ILD
RECRUITING · Phase 2
-
Omega-3D: Omega-3 for Diet-Driven Health Disparities
RECRUITING · Phase 2
-
Microbiome Metabolites and Alcohol in HIV to Reduce CVD RCT
RECRUITING · Phase 2
-
Virtual Care Strategies to Improve Participation in Cardiac Rehabilitation Among Veterans
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00870129 · 135 participants · NA
Magnetic Resonance (MR) Imaging to Determine High Risk Areas in Patients With Malignant Gliomas and to Design Potential Radiation Plans and to Examine Metabolite Changes in Gliomas and Other Solid Tumors
- NCT03666000 · 135 participants · Phase 1
Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)
- NCT04891510 · 135 participants · NA
A Comparative Analysis of REVOLVE, LipoGrafter, and Viality in Autologous Fat Grafting During Breast Surgery
- NCT05121051 · 135 participants · Phase 2
Testing the Effect of the Broccoli Seed and Sprout Extract, Avmacol ES, on the Cancer Causing Substances of Tobacco in Heavy Smokers
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI